QIAGEN to Market Test That Shows if Prostate Cancer Is Responding to Two Therapies

QIAGEN to Market Test That Shows if Prostate Cancer Is Responding to Two Therapies
QIAGEN will begin marketing a test that Johns Hopkins University developed to detect whether advanced prostate cancer patients are failing to respond to the widely used therapies Zytiga (enzalutamide) and Xtandi (abiraterone). If doctors know that a prostate cancer patient is resistant to the drugs, they can develop a more tailored treatment. The test, called AdnaTest Prostate Cancer Panel AR-V7, will detect that resistance. In to the test being used in treatment, researchers can use it to help select patients for clinical trials. Prostate cancer is the third leading cause of cancer death among American men. Zytiga and Xtandi are hormone therapies for patients with castration-resistant prostate cancer (CRPC). They block the a
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *